

CITATION REPORT

List of articles citing

Treatment of hepatitis C virus infection with direct-acting antiviral agents: 100% cure?

DOI: 10.1111/liv.13673

Liver International, 2018, 38 Suppl 1, 7-13.

Source: <https://exaly.com/paper-pdf/69094257/citation-report.pdf>

Version: 2024-04-24

This report has been generated based on the citations recorded by exaly.com for the above article. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

#	Paper	IF	Citations
114	Glucose Metabolism Changes in Patients with Chronic Hepatitis C Treated with Direct Acting Antivirals. 2018 , 2018, 6095097		10
113	Theaflavins, polyphenols of black tea, inhibit entry of hepatitis C virus in cell culture. 2018 , 13, e0198226		47
112	Hepatitis C virus genetic diversity by geographic region within genotype 1-6 subtypes among patients treated with glecaprevir and pibrentasvir. 2018 , 13, e0205186		8
111	Hepatitis virus (HCV) diagnosis and access to treatment in a UK cohort. 2018 , 18, 461		13
110	Chronic Hepatitis C Association with Diabetes Mellitus and Cardiovascular Risk in the Era of DAA Therapy. 2018 , 2018, 6150861		31
109	Novel Uridine Glycoconjugates, Derivatives of 4-Aminophenyl 1-Thioglycosides, as Potential Antiviral Compounds. 2018 , 23,		2
108	Anti-Hepatitis C Virus Activity of Uridine Derivatives of 2-Deoxy Sugars. 2018 , 23,		3
107	An educate, test, and treat programme towards elimination of hepatitis C infection in Egypt: a community-based demonstration project. 2018 , 3, 778-789		32
106	A village without hepatitis C in Egypt: will micro-elimination lead to macro-elimination?. 2018 , 3, 734-736		4
105	Identifying cirrhosis, decompensated cirrhosis and hepatocellular carcinoma in health administrative data: A validation study. 2018 , 13, e0201120		53
104	Pretreatment Hepatitis C Virus NS5A/NS5B Resistance-Associated Substitutions in Genotype 1 Uruguayan Infected Patients. 2018 , 2018, 2514901		10
103	Real life rates of sustained virological response (SVR) and predictors of relapse following DAA treatment in genotype 3 (GT3) patients with advanced fibrosis/cirrhosis. 2018 , 13, e0200568		7
102	Sphingolipids as Potential Therapeutic Targets against Enveloped Human RNA Viruses. 2019 , 11,		14
101	Setting ambitious targets for surveillance and treatment rates among patients with hepatitis C related cirrhosis impacts the cost-effectiveness of hepatocellular cancer surveillance and substantially increases life expectancy: A modeling study. 2019 , 14, e0221614		4
100	Direct antiviral therapy for treatment of hepatitis C: A real-world study from Brazil. 2019 , 18, 849-854		17
99	Pretherapeutic Evaluation of the Patients with HCV Infection. 2019 , 59-64		
98	Hepatitis C virus and cumulative infections are associated with atherogenic cardiovascular events in HIV-infected subjects. 2019 , 169, 104527		2

97	A proof-of-concept study in HCV-infected Huh7.5 cells for shortening the duration of DAA-based triple treatment regimens. 2019 , 116, 108976	3
96	Scaffold hybridization strategy towards potent hydroxamate-based inhibitors of viruses and species. 2019 , 10, 991-1006	4
95	A novel point-of-care oral anti-HCV assay: Is it reliable for screening hepatitis C virus infection in the era of direct-acting antivirals?. 2019 , 14, e0211795	1
94	Abstracts. <i>Liver International</i> , 2019 , 39, 2420-2468	7.9
93	Effect of adding daclatasvir in sofosbuvir-based therapy in genotype 3 hepatitis C: real-world experience in Pakistan. 2019 , 31, 1035-1039	4
92	Efficacy and safety of treatment of chronic hepatitis C with sofosbuvir and ribavirin with or without peginterferon: a French prospective real-life cohort study of unselected 211 patients. 2019 , 31, 1270-1274	1
91	Prevalence of thyroid stimulating hormone dysfunction among sofosbuvir-treated HCV-infected patients: A real-world clinical experience. 2019 , 91, 514-517	8
90	In a Critical State: Ongoing Barriers to Treatment for Hepatitis C Virus (HCV). 2019 , 132, 547-549	3
89	Ribavirin-induced down-regulation of CCAAT/enhancer-binding protein β leads to suppression of lipogenesis. 2019 , 476, 137-149	5
88	Synthesis and anti-HCV activity of Ed-2Rdeoxy-2R β -chloro-2R β fluoro and Ed-2Rdeoxy-2R β -bromo-2R β fluoro nucleosides and their phosphoramidate prodrugs. 2019 , 27, 664-676	2
87	Very late relapse in an HCV genotype 3-infected patient treated with direct-acting antivirals (DAA). 2020 , 75, 252-253	1
86	Direct-acting antivirals improve endothelial function in patients with chronic hepatitis: a prospective cohort study. 2020 , 15, 263-271	14
85	Introduction and General Principles. 2020 , 228-231	
84	A dendritic cell receptor-targeted chimeric immunotherapeutic protein (C-HBV) for the treatment of chronic hepatitis B. 2020 , 16, 756-778	5
83	Improving access to care for people who inject drugs: Qualitative evaluation of project ITTREAT-An integrated community hepatitis C service. 2020 , 27, 176-187	9
82	Adherence to pan-genotypic glecaprevir/pibrentasvir and efficacy in HCV-infected patients: A pooled analysis of clinical trials. <i>Liver International</i> , 2020 , 40, 778-786	7.9 13
81	A Novel Cis-Acting RNA Structural Element Embedded in the Core Coding Region of the Hepatitis C Virus Genome Directs Internal Translation Initiation of the Overlapping Core+1 ORF. 2020 , 21,	1
80	How effective is direct acting antiviral therapy in curing chronic hepatitis C among individuals who actively inject drugs?. 2020 , 23, 1-2	

79	Iminosugars: A host-targeted approach to combat Flaviviridae infections. 2020 , 184, 104881	11
78	Descriptive epidemiology of incidence and mortality of primary liver cancer in 185 countries: evidence from GLOBOCAN 2018. 2020 , 50, 1370-1379	19
77	Potential interactions between pangenotypic direct-acting antivirals and concomitant cardiovascular therapies in patients with chronic hepatitis C virus infection. 2020 , 48, 300060520964659	0
76	miRNAs as Potential Biomarkers for Viral Hepatitis B and C. 2020 , 12,	14
75	Electroanalytical investigation and determination of hepatitis C antiviral drug ledipasvir at a non-modified boron-doped diamond electrode. 2020 , 108, 107962	15
74	Upregulation of the Long Non-Coding RNA HULC by Hepatitis C Virus and its Regulation of Viral Replication. 2020 ,	2
73	Eradicating hepatitis C: Are novel screening strategies for people who inject drugs cost-effective?. 2020 , 82, 102811	1
72	Hepatitis C diagnosis and treatment, impact on engagement and behaviour of people who inject drugs, a service evaluation, the hooked C project. 2020 , 27, 576-584	0
71	High success rates for the use of sofosbuvir/ombitasvir/paritaprevir/ritonavir + ribavirin and sofosbuvir/simeprevir/daclatasvir + ribavirin in retreatment of chronic hepatitis C infection after unsuccessful sofosbuvir/daclatasvir therapy: a real-life experience. 2020 , 165, 1633-1639	5
70	MK-571, a Cysteinyl Leukotriene Receptor 1 Antagonist, Inhibits Hepatitis C Virus Replication. 2020 , 64,	2
69	Rapid visual detection of hepatitis C virus using a reverse transcription loop-mediated isothermal amplification assay. 2021 , 102, 440-445	5
68	Effectiveness and safety of glecaprevir/pibrentasvir in chronic hepatitis C patients: Results of the Italian cohort of a post-marketing observational study. 2021 , 53, 612-619	3
67	COVID-19: Discovery, diagnostics and drug development. 2021 , 74, 168-184	133
66	Off-Target Profiling Demonstrates that Remdesivir Is a Highly Selective Antiviral Agent. 2021 , 65,	17
65	Full-length genome sequencing of RNA viruses-How the approach can enlighten us on hepatitis C and hepatitis E viruses. 2021 , 31, e2197	
64	Natural prevalence of NS3 gene resistance-associated substitutions (RASs) in patients with chronic hepatitis C from the state of Par�Brazil. 2021 , 292, 198251	3
63	Current Management of Patients with HCV Genotype 4. 2021 , 119-127	
62	Efficacy and Safety of Glecaprevir/Pibrentasvir in Patients with Chronic HCV Infection. 2021 , 9, 125-132	1

61	Antiviral treatment for hepatitis C is associated with a reduced risk of atherosclerotic cardiovascular outcomes: A systematic review and meta-analysis. 2021 , 28, 664-671		2
60	Treating paediatric hepatitis C in the era of direct-acting antiviral agents. <i>Liver International</i> , 2021 , 41, 1189-1200	7.9	
59	Evaluating and communicating hepatitis C cascades of care data in Tayside, Scotland: A journey towards elimination. 2021 , 28, 909-915		
58	9-Sulfonyl-9(H)-Purine Derivatives Inhibit HCV Replication Via their Degradation Species. 2021 , 55, 36-45		
57	Serum Laminin α Monomer as a Diagnostic and Predictive Biomarker for Hepatocellular Carcinoma. 2021 , 74, 760-775		5
56	Screening, confirmation, and treatment rates of hepatitis C virus infection in a tertiary academic medical center in South Korea. 2021 , 36, 2479-2485		0
55	Complications of primary total hip arthroplasty in human immunodeficiency virus-positive patients with femoral head osteonecrosis. 2021 , 11207000211005750		0
54	Hepatitis C Virus Prevalence and Risk Factors in a Village in Northeastern Romania-A Population-Based Screening-The First Step to Viral Micro-Elimination. 2021 , 9,		0
53	Real-World Outcomes in Historically Underserved Patients with Chronic Hepatitis C Infection Treated with Glecaprevir/Pibrentasvir. 2021 , 10, 2203-2222		2
52	New therapies for hepatitis delta virus infection. <i>Liver International</i> , 2021 , 41 Suppl 1, 30-37	7.9	5
51	Progress and challenges in the comprehensive management of chronic viral hepatitis: Key ways to achieve the elimination. 2021 , 27, 4004-4017		1
50	Outcomes of the CT2 study: A one-stop-shop for community-based hepatitis C testing and treatment in Yangon, Myanmar. <i>Liver International</i> , 2021 , 41, 2578-2589	7.9	8
49	Key Metabolic Enzymes Involved in Remdesivir Activation in Human Lung Cells. 2021 , 65, e0060221		11
48	Liver Cirrhosis, Etiology and Clinical Characteristics Disparities Among Minority Population. 2021 , 1		0
47	DREKT ETKİNTİBAL TEDAVİALAN KRONİK HEPATİT C HASTALARINDA ALFA FETOPROTEİN SONUÇLARININ DEĞERLENDİRİLMESİ 220-228		
46	Sofosbuvir/velpatasvir for the treatment of hepatitis C in pediatric patients. 2021 , 15, 1097-1105		0
45	Cost-effectiveness and system-wide impact of using Hepatitis C-viremic donors for heart transplant. 2021 ,		1
44	Prevalence of resistance-associated substitutions and phylogenetic analysis of hepatitis C virus infection in Russia. 2021 , 113, 36-42		1

43	Hepatitis C reinfection by treatment pathway among people who inject drugs in Tayside, Scotland. 2021 , 28, 1744-1750	1
42	Urinary metabolomics of HCV patients with severe liver fibrosis before and during the sustained virologic response achieved by direct acting antiviral treatment. 2021 , 143, 112217	0
41	The Intersection of Cognitive Ability and HIV: A Review of the State of the Nursing Science. 2021 , 32, 306-321	7
40	Theaflavins, polyphenols of black tea, inhibit entry of hepatitis C virus.	1
39	A new tool for estimating liver cancer risk after a hepatitis C virus cure. 2020 , 9, 791-793	1
38	Detection of anti-protease inhibitors resistance mutations in HCV strains infecting treatment-naïve chronic patients from Romania. 2018 , 26, 443-449	1
37	A Real-Life Study of New Antiviral Therapies in a High Prevalence Geographical Area for Hepatitis C Virus Infection. 2018 , In Press,	0
36	Clonal Expansion of Infected CD4+ T Cells in People Living with HIV. 2021 , 13,	3
35	Care After Cure: Long-term Follow-up in Hepatitis C. 1	
34	Louisiana Medicaid access for treatment and care for hepatitis C virus (LA-MATCH) project: A cross-sectional study protocol. 2021 , 16, e0257437	
33	WOMEN CO-INFECTED WITH HIV AND VHC. PART 1. PSYCHOSOCIAL CHARACTERISTIC AND READINESS TO ANTIVIRAL THERAPY. 2018 , 10, 30-39	5
32	Hepatitis C virus screening at a Veterans Administration Hospital in New York City. 2020 , 33, 646-651	2
31	Noninvasive assessment of liver fibrosis in chronic hepatitis C virus patients compared to liver biopsy: the experience of tertiary level hospital in Serbia. 2020 , 111, 197-202	2
30	Nucleoside Antiviral Agents for HCV. 2020 , 906-914	
29	Current international guidelines for the management of patients with chronic viral hepatitis C. 2020 , 72-77	
28	Entecavir prevents HBV reactivation during direct acting antivirals for HCV/HBV dual infection: a randomized trial. 2021 ,	0
27	Safety and efficacy of glecaprevir and pibrentasvir in north Tohoku Japanese patients with genotype 1/2 hepatitis C virus infection.. 2022 , 5, e458	2
26	Barriers to hepatitis C diagnosis and treatment in the DAA era: Preliminary results of a community-based survey of primary care practitioners. 2022 , 5, 96-100	

25	The efficacy of Elbasvir/Grazoprevir fixed-dose combination for 8 weeks in HCV treatment and health-related quality of life (HRQoL) in treatment-naïve, non-cirrhotic, genotype 4-infected patients (ELEGANT-4): A single-center, single-arm, open-label, phase 3 trial.. 2022 ,	
24	Mimetismo molecular entre autoproteínas da tireoide e poliproteínas do vírus da hepatite C. 2021 , 181-214	
23	Long-term outcomes of hemostatic therapy for variceal bleeding and the challenge pending in the post-direct-acting antivirals era.. 2022 , 85, 7-14	
22	IL-26 inhibits hepatitis C virus replication in hepatocytes.. 2021 ,	1
21	Real-world outcomes of rapid regional hepatitis c virus treatment scale-up among people who inject drugs in Tayside, Scotland. 2021 ,	3
20	Conspicuous Response to Direct-Acting Antivirals in Chronic Hepatitis C-related Immune Thrombocytopenia: A Case Report.. 2022 , 14, e24193	
19	Design and Synthesis of Novel Bis-Imidazolyl Phenyl Butadiyne Derivatives as HCV NS5A Inhibitors. 2022 , 15, 632	0
18	Observer-based controller for treatment of hepatitis C infection using fractional order model.	
17	Evaluation of Cardiovascular Risk Factors after Hepatitis C Virus Eradication with Direct-Acting Antivirals in a Cohort of Treatment-Naïve Patients without History of Cardiovascular Disease. 2022 , 11, 4049	0
16	Identification of NS5B resistance against SOFOSBUVIR in hepatitis C virus genotype 3a, naive and treated patients.	0
15	Assessment of the sofosbuvir + daclatasvir (D) ribavirin treatment and the prognostic efficacy of interferon-gamma induced protein 10, macrophage inflammatory-1-beta, and C-reactive protein in Hepatitis C Egyptian patients therapy outcome. 2022 , 6, 109	0
14	Strategies for delivery of antiviral agents. 2023 , 407-492	0
13	Synthesis of novel azasugar-containing 2'-C-Me 9-deaza nucleosides as potential anti-hepatitis C virus agents. 1-11	0
12	HCV infection characteristics, treatment uptake and outcomes in patient with diabetes mellitus. 2022 , 22,	1
11	Hepatitis D virus: Improving virological knowledge to develop new treatments. 2022 , 105461	0
10	Novel 6-Aminoquinazolinone Derivatives as Potential Cross GT1-4 HCV NS5B Inhibitors. 2022 , 14, 2767	0
9	Beyond bulevirtide: alternative therapeutic options for the management of HDV.	0
8	Impact of hepatitis C virus eradication with direct-acting antivirals on glycidic metabolism. 2022 ,	0

- 7 Cost-effectiveness of direct-acting antivirals for chronic hepatitis C virus in the United States from a payer perspective. **2022**, 28, 1138-1148 ○
- 6 Pilot Outreach Program in Remedis: The Promising Step toward HCV Elimination among People Who Inject Drugs. **2023**, 20, 501 ○
- 5 Perspectives on Adherence from the ACTG 5360 MINMON Trial: A Minimum Monitoring Approach with 12 Weeks of Sofosbuvir/Velpatasvir in Chronic Hepatitis C Treatment. ○
- 4 The effect of different direct antivirals on hepatic steatosis in nondiabetic and naïve hepatitis C-infected Egyptian patients. **2023**, 35, ○
- 3 The role of miRNAs in liver diseases: Potential therapeutic and clinical applications. **2023**, 243, 154375 ○
- 2 Cost-effectiveness and economic investment to eliminate chronic hepatitis C in Mexico. ○
- 1 Efficacy and safety of direct-acting antiviral regimen for patients with hepatitis C virus genotype 2: A systematic review and meta-analysis. ○